A Comparison of Mometasone Furoate DPI Versus Budesonide DPI in Budesonide DPI in Asthmatics (Study P04880)

Inclusion Criteria: * Subjects must be 12 years of age or older of either gender, who (and their parent/guardian if the subject is under the age of 20) must demonstrate their willingness to sign and write informed consent. * Subjects must have had a history of asthma for at least 6 months. * The subject must be diagnosed mild persistent or moderate persistent asthma and his/her FEV1 must be \>= 60% of predicted normal at both the Screening and Baseline visits, when short-acting inhaled beta agonists have been withheld for at least six hours and long-acting inhaled beta agonists have been withheld for at least 12 hours. * Subjects must demonstrate an increase in absolute FEV1 of \>= 12%, with an absolute volume increase of at least 200 mL, after reversibility testing at the Screening visit, or historically within the past 12 months; Subjects without documented absolute FEV1 of \>= 12% in reversibility test within the past 12 months need to demonstrate a positive result in Methacholine challenge test. * If Subjects with ICS treatment have been using ICS on a daily basis for at least 4 weeks prior to Screening. For the two weeks prior to Screening, subjects must have been on a stable regimen of ICS. Each ICS dose is shown in following: * Flunisolide between 1000 to 2000 mcg/day * Budesonide between 400 to 800 mcg/day * Triamcinolone acetonide between 600 to 1600 mcg/day * Beclomethasone Dipropionate between 252 to 840 mcg/day * Fluticasone propionate between 200 to 5…